SCM
INBX icon

Soleus Capital Management’s Inhibrx INBX Stock Holding History

Soleus Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.81M Buy
131,000
+106,000
+424% +$7.86M 0.36% 56
2025
Q4 		$1.98M Buy
+25,000
New +$1.7M 0.07% 80
2024
Q3 		– Sell
-88,470
Closed -$1.25M – 96
2024
Q2 		$1.25M Buy
+88,470
New +$1.38M 0.11% 82

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Soleus Capital Management's INBX Position: Q1 2026 in Review

Soleus Capital Management increased its Inhibrx (INBX) stake by 424% in Q1 2026, buying an estimated $7.86M and bringing the position to 131,000 shares worth $8.81M. The position accounts for 0.36% of the portfolio, ranked #56.

Soleus Capital Management first reported a position in INBX in Q2 2024 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Soleus Capital Management held 131,000 shares of Inhibrx worth $8.81M as of Q1 2026.
  • Soleus Capital Management bought 106,000 Inhibrx shares in Q1 2026, an estimated $7.86M.
  • Inhibrx made up 0.36% of Soleus Capital Management's portfolio in Q1 2026, its #56 holding.
  • Soleus Capital Management first reported a position in Inhibrx in Q2 2024 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.